TimesSquare Capital Management LLC Invests $18.04 Million in Kymera Therapeutics, Inc. $KYMR

TimesSquare Capital Management LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 157,327 shares of the company’s stock, valued at approximately $18,041,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after buying an additional 98 shares in the last quarter. US Bancorp DE grew its stake in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after buying an additional 166 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Kymera Therapeutics by 3.6% during the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after buying an additional 235 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after buying an additional 252 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after acquiring an additional 287 shares during the last quarter.

Insider Activity

In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $106.50, for a total value of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer owned 244,883 shares in the company, valued at $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 3,604,813 shares of company stock worth $387,557,004. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $121.41 on Tuesday. Kymera Therapeutics, Inc. has a one year low of $39.84 and a one year high of $130.05. The company has a 50 day moving average of $106.11 and a 200-day moving average of $90.76. The stock has a market cap of $10.10 billion, a price-to-earnings ratio of -37.47 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same period in the previous year, the firm posted ($0.95) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 465.2% compared to the same quarter last year. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Loop Capital set a $97.00 target price on Kymera Therapeutics in a report on Monday, June 8th. Mizuho raised their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Citigroup reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Morgan Stanley restated an “overweight” rating and set a $135.00 target price on shares of Kymera Therapeutics in a report on Thursday, August 6th. Twenty investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.